Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | RAF1 | P04049 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 6/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306976 | 0.90 | KDR (0.54) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL2029492 | 0.90 | KDR (0.54) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL621164 | 0.86 | KDR (0.51) | KDRRAF1EPHX2BRAFCSF1R | |
| SCHEMBL6427439 | 0.85 | KDR (0.50) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL6426864 | 0.85 | KDR (0.50) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL12355376 | 0.85 | KDR (0.50) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL2025625 | 0.84 | DDR2 (0.52) | KDRRAF1EPHX2BRAFCSF1R | |
| SCHEMBL617620 | 0.83 | KDR (0.50) | KDRRAF1EPHX2BRAFCSF1R | |
| SCHEMBL29130657 | 0.83 | KDR (0.53) | KDRRAF1EPHX2GCKBRAF | |
| SCHEMBL6387865 | 0.82 | KDR (0.61) | KDRRAF1EPHX2BRAFCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | KDR 4185/4885RAF1 860/4885EPHX2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.